Research Analysts Issue Forecasts for ALDX Q2 Earnings

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for shares of Aldeyra Therapeutics in a research note issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman anticipates that the biotechnology company will post earnings of ($0.23) per share for the quarter. The consensus estimate for Aldeyra Therapeutics' current full-year earnings is ($0.92) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics' Q4 2025 earnings at ($0.33) EPS.

Other research analysts also recently issued research reports about the company. HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a report on Friday, April 4th. BTIG Research decreased their target price on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a research report on Monday, April 7th.

Aldeyra Therapeutics Price Performance

Shares of NASDAQ:ALDX traded up $0.18 on Tuesday, hitting $2.19. The company's stock had a trading volume of 1,881,935 shares, compared to its average volume of 701,735. The company has a 50-day simple moving average of $5.23 and a 200 day simple moving average of $5.17. Aldeyra Therapeutics has a 1 year low of $1.14 and a 1 year high of $7.20. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. The company has a market capitalization of $130.76 million, a PE ratio of -2.33 and a beta of 0.94.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.30).

Insider Transactions at Aldeyra Therapeutics

In other news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the business's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the transaction, the insider now directly owns 5,875,851 shares in the company, valued at $8,343,708.42. The trade was a 36.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 8.50% of the company's stock.

Institutional Trading of Aldeyra Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Hsbc Holdings PLC purchased a new position in Aldeyra Therapeutics in the 4th quarter valued at about $52,000. Balyasny Asset Management L.P. acquired a new stake in shares of Aldeyra Therapeutics in the fourth quarter valued at approximately $56,000. Wealth Enhancement Advisory Services LLC acquired a new position in Aldeyra Therapeutics during the 1st quarter worth $63,000. Catalyst Funds Management Pty Ltd raised its stake in shares of Aldeyra Therapeutics by 2,083.3% in the 4th quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company's stock worth $65,000 after buying an additional 12,500 shares in the last quarter. Finally, Regal Investment Advisors LLC purchased a new stake in shares of Aldeyra Therapeutics during the fourth quarter valued at $66,000. 59.71% of the stock is owned by institutional investors and hedge funds.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.